AIFF

8-K - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

– Comes just weeks after Firefly confirmed its active public-private partnership with the U.S. Department of War – KENMORE, N.Y, June 02, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly" or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company advancing precision neuroscience, today announced the identification of a novel electrophysiological biomarker for Post-Traumatic Stress Disorder ("PTSD") using brain scans collected on its FDA-510(k)-cleared Evoke System. The biomarker discovery emanates partly from Firefly's previously announced public-private partnership with the U.S. Department of War ("DoW") to support the assessment and treatment of active-duty

S-8 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

S-3 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

8-K - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

8-K - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

D - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

- Firefly's total brain scan volumes have increased sequentially by higher percentages in each of the past four quarters - - Firefly is harnessing increased data and NVIDIA L40S GPU acceleration to power next-generation EEG/ERP processing, enabling new AI-driven biomarker discovery capabilities – - Milestone supports Firefly's goal of building and launching the world's first EEG/ERP-based foundation model of the human brain - KENMORE, N.Y., April 13, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly" or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and

10-K - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

Firefly's AI-powered, FDA-cleared EEG/ERP Technology is Being Deployed to Support Assessment and Treatment of PTSD and TBI in U.S. Service Members Partnership Represents a Significant Expansion of Company's Commercial Footprint into the U.S. Government and Defense Health Sectors KENMORE, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (NASDAQ:AIFF) ("Firefly," or the "Company"), today announced a partnership with the Department of War ("DoW") to support the assessment and treatment of active-duty U.S. service members and veterans suffering from Post-Traumatic Stress Disorder ("PTSD") and/or Traumatic Brain Injury ("TBI"). The genesis of this innovative public-private

3/A - FIREFLY NEUROSCIENCE, INC. (0000803578) (Issuer)

Over 22 million Americans are diagnosed with ADHD — yet an objective biological marker for distinguishing between its three distinct subtypes has, to date, remained elusive1 Firefly's AI-powered EEG/ERP technology may help identify which ADHD subtype a patient has — potentially complementing subjective symptom checklists with neural signal-based precision Subtype identification could change the clinical equation: Firefly's platform may help clinicians determine the most appropriate treatment type, inform dosage decisions, and potentially monitor whether an intervention is working The breakthrough advances Firefly's mission to build the world's first EEG/ERP brain foundation model — bein

8-K - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

4 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Issuer)

4 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Issuer)

GAD Therapies Market Set to Explode to $4.26B by 2033 as Demand Rockets for Innovative Anxiety Solutions NEW YORK, March 5, 2026 /CNW/ -- Market News Updates News Commentary - Treatments for Generalized Anxiety Disorder (GAD) are getting better and more accessible, which is good news for millions of people dealing with constant worry and stress. Traditional medications like anti-anxiety drugs and antidepressants still play a big role, but therapy options such as cognitive-behavioral therapy and mindfulness techniques are also helping people manage symptoms without relying only on medication. Digital mental health tools and telehealth visits are making treatment easier to access, especially f

- Company reports 20-fold expansion of commercial footprint, 33-fold increase in EEG/ERP brain scan volumes -  - Harnessing increased data and cutting-edge supercomputing potentially unlocks new AI-driven biomarker discovery capabilities and significantly advances Firefly on its path of building a foundation model of the human brain - KENMORE, N.Y., March 04, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly" or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce a greater than 20-fold expansion of its commercial f

8-K - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

424B5 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

8-K - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

EFFECT - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

S-3 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

S-8 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

 – Quarterly performance characterized by higher revenues, reduced cost structure and improved bottom line – – Successful business integration drives 10.9% sequential quarter-over-quarter EEG/ERP scan volumes and 30% sequential revenue growth – KENMORE, N.Y., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today reported financial results for the three and nine months ended September 30, 2025. Business Highlights Third quarter 2025 revenue grew more than tenfold year-over-year and 30% s

10-Q - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)